Work

What therapies are most effective for patients with double-expressor lymphoma in terms of survival outcomes?

Year: 2026

Type: article

Abstract: Tucidinostat combined with R-CHOP shows promise in improving survival outcomes for patients with double-expressor lymphoma compared to R-CHOP alone, although further dedicated studies are needed to establish definitive therapeutic strategies for this high-risk group.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.24015740

Author: Tripdatabase

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7225389036

FWCI:

Cites:

Cited by:

Related to: 10